A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

Carpten, J. D., Faber, A. L., Horn, C. L., Donoho, G. P., Briggs, S., Robbins, C. M., Hostetter, G. H., Boguslawski, S. J., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,322

A large-scale RNAi screen in human cells identifies new components of the p53 pathway

Berns, K., Hijmans, E. M., Mullenders, J., Brummelkamp, T. R., Velds, A., Heimerikx, M., Kerkhoven, R. M., Madiredjo, M., Nijkamp, W., Weigelt, B., et al. (2004) · Nature Cell Biology · doi:10.1038/nature02371 · Cited by 1,080

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

Sergina, N. V., Rausch, M., Wang, D., Blair, J. A., Hann, B. C., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 993

Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)

Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 886

PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast Carcinoma

Saal, L. H., Holm, K., Maurer, M. S., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., MANSUKHANI, M. M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 877

PIK3CA mutations are associated with increased tumor aggressiveness and Akt activation in gastric cancer

Kim, J., Lee, H. S., Nam, K. H., Ahn, S., Kim, J. W., Ahn, S.-H., Park, D. J., Kim, H., & Lee, K. (2017) · Oncotarget · doi:10.18632/oncotarget.18770 · Cited by 47

The Role of PI3K in Met Driven Cancer: A Recap

Hervieu, A., & Kermorgant, S. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00086 · Cited by 47

Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer

Mezynski, J., Farrelly, A. M., Cremona, M., Carr, A., Morgan, C., Workman, J. A., Armstrong, P., McAuley, J., Madden, S. F., Fay, J., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02842-1 · Cited by 44

First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2 -altered NSCLC: a retrospective real-world POLISH study

Yang, G., Yang, Y., Liu, R., Li, W., Xu, H., Hao, X., Li, J., Xing, P., Zhang, S., Ai, X., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221082339 · Cited by 44

Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs

Gámez-Chiachio, M., Sarrió, D., & Moreno‐Bueno, G. (2022) · Cancers · doi:10.3390/cancers14184543 · Cited by 49

Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions

Yardley, D. A. (2013) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s10071 · Cited by 45

Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions

Troxell, M. L., Brunner, A. L., Neff, T. L., Warrick, A., Beadling, C., Montgomery, K. D., Zhu, S., Corless, C. L., & West, R. B. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.55 · Cited by 46

The Role of PTEN in Tumor Angiogenesis

Rodriguez, S., & Huynh‐Do, U. (2011) · Journal of Oncology · doi:10.1155/2012/141236 · Cited by 44

Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models

Wu, X.-H., Zhang, J., Zhen, R., Lv, J., Li, Z., Su, X., Zhu, G., Gavine, P. R., Xu, L., Lu, S., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-180 · Cited by 44

Advances in systemic therapy for metastatic breast cancer: future perspectives

Corona, S. P., Sobhani, N., Ianza, A., Roviello, G., Mustacchi, G., Bortul, M., Zanconati, F., & Generali, D. (2017) · Medical Oncology · doi:10.1007/s12032-017-0975-5 · Cited by 44

Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer

Sabine, V. S., Sims, A. H., Macaskill, E. J., Renshaw, L., Thomas, J. S. J., Dixon, J. M., & Bartlett, J. M. S. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0928-6 · Cited by 44

Insulin-Like Growth Factor-1 Receptor Signaling Increases the Invasive Potential of Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer Cells via Src-Focal Adhesion Kinase and Forkhead Box Protein M1

Sanabria-Figueroa, E., Donnelly, S., Foy, K. C., Buss, M. C., Castellino, R. C., Paplomata, E., Taliaferro-Smith, L. D., Kaumaya, P. T. P., & Nahta, R. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.095380 · Cited by 46

Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer

Wang, Q., Li, S.-H., Wang, H., Xiao, Y. Q., Şahin, Ö., Brady, S. W., Li, P., Ge, H., Jaffee, E. M., Muller, W. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1339-t · Cited by 45

Advances in Molecular and Clinical Subtyping of Breast Cancer and Their Implications for Therapy

Cadoo, K. A., Traina, T. A., & King, T. A. (2013) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2013.06.006 · Cited by 43

Inhibition of the PI3K Pathway: Hope We Can Believe in?

van der Heijden, M. S., & Bernards, R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3004 · Cited by 40

Omics and therapy – A basis for precision medicine

Garay, J. P., & Gray, J. W. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.009 · Cited by 42

A Bispecific HER2-Targeting FynomAb with Superior Antitumor Activity and Novel Mode of Action

Brack, S., Attinger-Toller, I., Schade, B., Mourlane, F., Klupsch, K., Woods, R., Hachemi, H., von der Bey, U., Koenig-Friedrich, S., Bertschinger, J., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0046-t · Cited by 43

It's Diagnostics, Stupid

Bernards, R. (2010) · Cell · doi:10.1016/j.cell.2010.03.018 · Cited by 43

Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars

Jackisch, C., Lammers, P. E., & Jacobs, I. A. (2017) · The Breast · doi:10.1016/j.breast.2017.01.010 · Cited by 43

miR‐200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer

Tang, H., Song, C., Ye, F., Gao, G., Ou, X., Zhang, L., Xie, X., & Xie, X. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14681 · Cited by 43

Sea Cucumber Intestinal Peptide Induces the Apoptosis of MCF-7 Cells by Inhibiting PI3K/AKT Pathway

Wei, W., Fan, X.-M., Jia, S., Zhang, X., Zhang, Z., Zhang, X.-J., Zhang, J.-X., & Zhang, Y. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.763692 · Cited by 48

Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure–Activity Relationship Studies

Yu, X., Xu, J., Shen, Y., Cahuzac, K. M., Park, K., Dale, B., Liu, J., Parsons, R. E., & Jin, J. J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02165 · Cited by 43

HER-2 as a Target for Breast Cancer Therapy

Ignatiadis, M., Desmedt, C., Sotiriou, C. P., de Azambuja, E., & Piccart, M. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1844 · Cited by 41

Jumping higher: is it still possible? The ALTTO trial challenge

Tomasello, G., de Azambuja, E., Dinh, P., Snoj, N., & Piccart, M. J. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.12.1883 · Cited by 42

Inhibition of tumor promoting signals by activation of SSTR2 and opioid receptors in human breast cancer cells

Kharmate, G., Rajput, P. S., Lin, Y., & Kumar, U. (2013) · Cancer Cell International · doi:10.1186/1475-2867-13-93 · Cited by 42

New tools for old drugs: Functional genetic screens to optimize current chemotherapy

Gerhards, N. M., & Rottenberg, S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.01.001 · Cited by 43

NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer

Cai, Y., Yousef, A., Grandis, J. R., & Johnson, D. E. (2019) · Advances in Biological Regulation · doi:10.1016/j.jbior.2019.100653 · Cited by 42

EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer

Rose, M., Maurer, A., Wirtz, J., Bleilevens, A., Waldmann, T., Wenz, M., Eyll, M., Geelvink, M., Gereitzig, M., Rüchel, N., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01465-y · Cited by 42

PIK3CA Hotspot Mutation Scanning by a Novel and Highly Sensitive High-Resolution Small Amplicon Melting Analysis Method

Vorkas, P. A., Πουμπουρίδου, Ν., Agelaki, S., Κroupis, C., Georgoulias, V., & Lianidou, E. S. (2010) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.100008 · Cited by 43

In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells

Ozbay, T., Durden, D. L., Liu, T., O'Regan, R. M., & Nahta, R. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1075-9 · Cited by 41

Understanding resistance to targeted cancer drugs through loss of function genetic screens

Berns, K., & Bernards, R. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.10.002 · Cited by 41

Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status

Nuciforo, P. G., Aura, C. M., Holmes, E. M., Prudkin, L., Jimenez, J., Martinez, P., Ameels, H., de la Peña, L., Ellis, C., Eidtmann, H., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv175 · Cited by 41

A simple and robust real-time qPCR method for the detection of PIK3CA mutations

Garcia, V. A., Bartos, C., Keraite, I., Trivedi, U. H., Brennan, P. M., Kersaudy-Kerhoas, M., Gharbi, K., Oikonomidou, O., & Leslie, N. R. (2018) · Scientific Reports · doi:10.1038/s41598-018-22473-9 · Cited by 42

Mammalian Target of Rapamycin as a Rational Therapeutic Target for Breast Cancer Treatment

LoRusso, P. M. (2012) · Oncology · doi:10.1159/000343063 · Cited by 43

Overcoming Treatment Resistance in HER2-Positive Breast Cancer

Puglisi, F., Minisini, A. M., Angelis, C. D., & Arpino, G. (2012) · Drugs · doi:10.2165/11634000-000000000-00000 · Cited by 41

Flavopiridol Synergizes with Sorafenib to Induce Cytotoxicity and Potentiate Antitumorigenic Activity in EGFR/HER-2 and Mutant RAS/RAF Breast Cancer Model Systems

Nagaria, T. S., Williams, J. L., Leduc, C., Squire, J. A., Greer, P. A., & Sangrar, W. (2013) · Neoplasia · doi:10.1593/neo.13804 · Cited by 39

Simplistic pathways or complex networks?

Jørgensen, C., & Linding, R. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.12.003 · Cited by 40

Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTTO phase III trial

Azim, H. A., Rothé, F., Aura, C. M., Bavington, M., Maetens, M., Rouas, G., Gebhart, G., Cenzano, C. G., Eidtmann, H., Baselga, J. M., et al. (2013) · The Breast · doi:10.1016/j.breast.2013.08.014 · Cited by 40

Functional genomic screening approaches in mechanistic toxicology and potential future applications of CRISPR-Cas9

Shen, H. M., McHale, C. M., Smith, M. T., & Zhang, L. (2015) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2015.01.002 · Cited by 40

Calpain‐1 expression is associated with relapse‐free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy

Storr, S. J., Woolston, C. M., Barros, F., Green, A. R., Shehata, M., Chan, S. Y. T., Ellis, I. O., & Martin, S. G. (2010) · International Journal of Cancer · doi:10.1002/ijc.25832 · Cited by 40

Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy

Sohn, J., Do, K. A., Liu, S., Chen, H., Mills, G. B., Hortobágyi, G. N., Meric‐Bernstam, F., & Gonzalez-Angulo, A. M. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt248 · Cited by 40

Enhanced PI3K p110α Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110α-Selective PI3K Inhibitor

Brady, S. W., Zhang, J., Seok, D., Wang, H., & Yu, D. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0518 · Cited by 40

Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options

Jiang, H., & Rugo, H. S. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015599389 · Cited by 40

Role of E542 and E545 missense mutations of PIK3CA in breast cancer: a comparative computational approach

Kumar, D. T., & Doss, C. G. P. (2016) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2016.1231082 · Cited by 40

Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1

Islam, S. S., Uddin, M. J., Noman, A. S. M., Akter, H., Dity, N. J., Basiruzzman, M., Uddin, K. M. F., Ahsan, J., Annoor, S., Alaiya, A. A., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.04.061 · Cited by 40

Can Systems Biology Understand Pathway Activation? Gene Expression Signatures as Surrogate Markers for Understanding the Complexity of Pathway Activation

Itadani, H., Mizuarai, S., & Kotani, H. (2008) · Current Genomics · doi:10.2174/138920208785133235 · Cited by 41

Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line.

Ekerljung, L., Lindborg, M., Gedda, L., Frejd, F., Carlsson, J., & Lennartsson, J. (2008) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2008.10.027 · Cited by 41

Optimal protocol for PTEN immunostaining; role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues

Maiques, Ó., Santacana, M., Valls, J., Pallarés, J., Mirantes, C., Gatius, S., Garcia-Dios, D. A., Amant, F. C., Pedersen, H. C., Dolcet, X., et al. (2013) · Human Pathology · doi:10.1016/j.humpath.2013.10.018 · Cited by 39

SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer

Gonzalez-Angulo, A. M., Krop, I. E., Akçakanat, A., Chen, H., Liu, S., Li, Y., Culotta, K. S., Tarco, E., Piha-Paul, S. A., Moulder-Thompson, S. L., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju493 · Cited by 39

PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells

Jegg, A.-M., Ward, T. M., Iorns, E. J., Hoe, N., Zhou, J., Liu, X., Singh, S., Landgraf, R., & Pegram, M. D. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2252-9 · Cited by 39

The voltage gated Ca2+-channel Cav3.2 and therapeutic responses in breast cancer

Pera, E., Kaemmerer, E., Milevskiy, M. J. G., Yapa, K. T. D. S., O’Donnell, J. S., Brown, M. A., Simpson, F., Peters, A. A., Roberts‐Thomson, S. J., & Monteith, G. R. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0299-0 · Cited by 39

TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting

Fountzilas, G., Giannoulatou, E., Alexopoulou, Z., Zagouri, F., Timotheadou, E. T., Papadopoulou, K., Lakis, S., Bobos, M., Poulios, C., Sotiropoulou, M. G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9022 · Cited by 39

Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer

Wen, W. X., Marcinkowski, E., Luyimbazi, D. T., Luu, T. H., Xing, Q., Yan, J., Wang, Y., Wu, J., Guo, Y., Tully, D. S., et al. (2019) · Cells · doi:10.3390/cells8091010 · Cited by 38

PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer

Kim, K., Kim, J., Sung, J. H., Suh, K. J., Lee, J. Y., Kim, S. H., Lee, J., Kim, J. W., Kim, Y. J., Kim, J. H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-68998-w · Cited by 40

PIK3CA mutation enrichment and quantitation from blood and tissue

Keraite, I., Garcia, V. A., García-Murillas, I., Beaney, M., Turner, N. C., Bartos, C., Oikonomidou, O., Kersaudy-Kerhoas, M., & Leslie, N. R. (2020) · Scientific Reports · doi:10.1038/s41598-020-74086-w · Cited by 40

Cancer Stem Cell-Targeted Therapeutic Approaches for Overcoming Trastuzumab Resistance in HER2-Positive Breast Cancer

Qiu, Y., Yang, L., Liu, H., & Luo, X. (2021) · Stem Cells · doi:10.1002/stem.3381 · Cited by 41

Molecular basis for therapy resistance

Lønning, P. E. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.005 · Cited by 38

EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma

Sundvall, M., Karrila, A., Nordberg, J., Grenman, R. A., & Elenius, K. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728211003716442 · Cited by 39

Small-molecule inhibitors of kinases in breast cancer therapy: recent advances, opportunities, and challenges

Bansal, I., Pandey, A. K., & Ruwali, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1244597 · Cited by 41

Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies

Asić, K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.004 · Cited by 38

PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer

Zhang, X., Park, J. S., Park, K. H., Kim, K. H., Jung, M., Chung, H. C., Rha, S. Y., & Kim, H. S. (2014) · Oncology · doi:10.1159/000366426 · Cited by 38

Refocusing the War on Cancer: The Critical Role of Personalized Treatment

Potti, A., Schilsky, R. L., & Nevins, J. R. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000643 · Cited by 38

A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer

Nam, S., Chang, H. R., Jung, H. R., Gim, Y., Kim, N. Y., Grailhe, R., Seo, H. R., Park, H. S., Balch, C., Lee, J., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.10.038 · Cited by 38

Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response

Lazaro, G., Smith, C. R., Goddard, L., Jordan, N., McClelland, R. A., Barrett-Lee, P. J., Nicholson, R. I., & Hiscox, S. (2013) · Endocrine Related Cancer · doi:10.1530/erc-13-0019 · Cited by 38

Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor

Zook, P., Pathak, H. B., Belinsky, M. G., Gersz, L., Devarajan, K., Zhou, Y., Godwin, A. K., von Mehren, M., & Rink, L. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0529 · Cited by 38

Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings

Leech, A. O., Vellanki, S. H., Rutherford, E. J., Keogh, A., Jahns, H., Hudson, L., O’Donovan, N., Sabri, S., Abdulkarim, B., Sheehan, K. M., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1064-1 · Cited by 38

Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma

Leblanc, O., Vacher, S., Lecerf, C., Jeannot, E., Klijanienko, J., Berger, F., Hoffmann, C., Calugaru, V., Badois, N., Chilles, A., et al. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0153 · Cited by 38

HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes

Hart, V., Gautrey, H., Kirby, J. A., & Tyson-Capper, A. J. (2020) · Oncotarget · doi:10.18632/oncotarget.27789 · Cited by 41

Modeling therapy resistance in genetically engineered mouse cancer models

Rottenberg, S., & Jonkers, J. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2007.11.002 · Cited by 38

PI3K Inhibition Overcomes Trastuzumab Resistance: Blockade of ErbB2/ErbB3 Is Not Always Enough

Hynes, N. E., & Dey, J. H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.004 · Cited by 38

Activity and resistance of trastuzumab according to different clinical settings

Tagliabue, E., Campiglio, M., Pupa, S. M., Ménard, S., & Balsari, A. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.06.002 · Cited by 37

Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer

Izar, B., Rotow, J. K., Gainor, J. F., Clark, J. W., & Chabner, B. A. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007807 · Cited by 38

Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo

Lopez, S., Cocco, E., Black, J., Bellone, S., Bonazzoli, E., Predolini, F., Ferrari, F., Schwab, C. L., English, D. P.-G., Ratner, E., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0383 · Cited by 37

A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers

Seyhan, A. A., Varadarajan, U., Choe, S. E., Liu, W., & RYAN, T. E. (2012) · Molecular BioSystems · doi:10.1039/c2mb05512k · Cited by 37

Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance

Cheng, X., Sun, Y., Highkin, M. K., Vemalapally, N., Jin, X., Zhou, B., Prior, J. L., Tipton, A. R., Li, S., Iliuk, A. B., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3558 · Cited by 38

Somatic alterations as the basis for resistance to targeted therapies

Blair, B. G., Bardelli, A., & Park, B. H. (2013) · The Journal of Pathology · doi:10.1002/path.4278 · Cited by 36

Inhibitors of phosphatidylinositol-3-kinase in cancer therapy

Ihle, N., & Powis, G. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2010.02.003 · Cited by 40

Complement pathway biomarkers and age-related macular degeneration

Gemenetzi, M. K., & Lotery, A. J. (2015) · Eye · doi:10.1038/eye.2015.203 · Cited by 39

Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models

Crafter, C., VINCENT, J. P., TANG, E. K. Y., Dudley, P., James, N. H., Klinowska, T. C. M., & Davies, B. R. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3062 · Cited by 36

Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness

Tserga, A., Chatziandreou, I., Michalopoulos, N. V., Patsouris, E., & Saetta, A. A. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-1938-5 · Cited by 36

CCNE1 amplification is associated with liver metastasis in gastric carcinoma

Kim, B., Shin, H. C., Heo, Y. J., Ha, S. Y., Jang, K., Kim, S. T., Kang, W. K., Lee, J., & Kim, K. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152434 · Cited by 36

Genetic and Epigenetic Modulation of Drug Resistance in Cancer: Challenges and Opportunities

Shah, K., & Rawal, R. (2020) · Current Drug Metabolism · doi:10.2174/1389200221666200103111539 · Cited by 36

Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer

Drullinsky, P. R., & Hurvitz, S. A. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05618-1 · Cited by 39

An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer

Elshazly, A. M., & Gewirtz, D. A. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.09 · Cited by 35

Unveiling the future of breast cancer therapy: Cutting-edge antibody-drug conjugate strategies and clinical outcomes

Sun, L., Jia, X., Wang, K., & Li, M. (2024) · The Breast · doi:10.1016/j.breast.2024.103830 · Cited by 40

Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas

Martín-Castillo, B., López‐Bonet, E., Cuyàs, E., Viñas, G., Pernas, S., Dorca, J., & Menéndez, J. A. (2015) · Oncotarget · doi:10.18632/oncotarget.6094 · Cited by 35

The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis

Ibrahim, E. M., Kazkaz, G. A., Al-Mansour, M. M., & Al‐Foheidi, M. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3480-6 · Cited by 35

Clinical Significance of PTEN and p-Akt Co-Expression in HER2-Positive Metastatic Breast Cancer Patients Treated with Trastuzumab-Based Therapies

Fabi, A., Metro, G., Benedetto, A. D., Nisticò, C., Vici, P., Melucci, E., Antoniani, B., Perracchio, L., Sperduti, I., Milella, M., et al. (2010) · Oncology · doi:10.1159/000312656 · Cited by 35

Genetically engineered mouse models of PI3K signaling in breast cancer

Klarenbeek, S., van Miltenburg, M. H., & Jonkers, J. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.02.003 · Cited by 36

Lapatinib, a Dual-Targeted Small Molecule Inhibitor of EGFR and HER2, in HER2-Amplified Breast Cancer: From Bench to Bedside

Tsang, R. Y., Sadeghi, S., & Finn, R. S. (2011) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s3783 · Cited by 35

Sequestosome 1/p62 facilitates HER2-induced mammary tumorigenesis through multiple signaling pathways

Cai-McRae, X., Zhong, H., & Karantza, V. (2014) · Oncogene · doi:10.1038/onc.2014.244 · Cited by 36

A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action

Damiano, V., Garofalo, S., Rosa, R., Bianco, R., Caputo, R., Gelardi, T., Merola, G., Racioppi, L., Garbi, C., Kandimalla, E. R., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1599 · Cited by 37

Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets

Błajecka, K., Borgström, A., & Arcaro, A. (2011) · Current Drug Targets · doi:10.2174/138945011795677773 · Cited by 34

Cancer Immunotherapy: The Dawn of Antibody Cocktails

Marrocco, I., Romaniello, D., & Yarden, Y. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8958-4_2 · Cited by 36

Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas

Kong, X., Zhang, K., Wang, X., Yang, X. C., Li, Y., Zhai, J., Xing, Z., Qi, Y., Gao, R., Feng, X., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s194137 · Cited by 35

Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem

Wahdan-Alaswad, R. S., Liu, B., & Thor, A. D. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2019.92 · Cited by 35

TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer

Gu, Y., Gao, H., Zhang, H., John, A. J., Zhu, X., Shivaram, S., Yu, J., Weinshilboum, R. M., & Wang, L. (2022) · Oncogene · doi:10.1038/s41388-022-02415-6 · Cited by 35

Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: Old targets new hope

De, P. K., Miskimins, K. W., Dey, N., & Leyland-Jones, B. R. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.12.002 · Cited by 34

Using Functional Genetics to Understand Breast Cancer BiologyPreprint

Ashworth, A., & Bernards, R. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003327 · Cited by 35

The immune checkpoint adenosine 2A receptor is associated with aggressive clinical outcomes and reflects an immunosuppressive tumor microenvironment in human breast cancer

Zohair, B., Chraa, D., Rezouki, I., Benthami, H., Razzouki, I., Elkarroumi, M., Olive, D., Karkouri, M., & Badou, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1201632 · Cited by 34

PTEN, PIK3CA, p-AKT, and p-p70S6K Status

Esteva, F. J., Guo, H., Zhang, S., Santa-Maria, C., Stone, S., Lanchbury, J. S., Sahin, A. A., Hortobagyi, G. N., & Yu, D. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090885 · Cited by 285

PI3 Kinase Activation and Response to Trastuzumab Therapy: What's neu with Herceptin Resistance?

Park, B. H., & Davidson, N. E. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.004 · Cited by 47

An Integrative Analysis of PIK3CA Mutation, PTEN, and INPP4B Expression in Terms of Trastuzumab Efficacy in HER2-Positive Breast Cancer

Sueta, A., Yamamoto, Y., Yamamoto‐Ibusuki, M., Hayashi, M., Takeshita, T., Yamamoto, S., & Iwase, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0116054 · Cited by 30

An evaluation of PI3K pathway activation on the efficacy of both trastuzumab and lapatinib.

Hu, X., Wang, L. P., Zhang, Q. L., Zhang, J., Guo, H., Sun, S., Wang, B. Y., Jia, Z., Shao, Z. M., & Wang, Z. H. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.541

Abstract P3-07-11: High activation of PI3K pathway defined by PIK3CA mutation, PTEN, and INPP4B expression are associated with trastuzumab efficacy in HER2-positive breast cancer

Sueta, A., Yamamoto, Y., Takeshita, T., Yamamoto‐Ibusuki, M., & Iwase, H. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-p3-07-11